Grace Therapeutics, Inc. GRCE
At closeNov 4, 2026, 4:00 PM EST
After hours · Nov 4, 4:00 PM ET
- YTD
- -47.69%
- 1 year
- -41.42%
- Market cap
- 38.08M
- EPS (ttm)
- -1.17
- Shares out
- 10.14M
- Forward P/E
- -2.90
- YTD return
- -47.69%
- 1-year return
- -41.42%
- Volume
- 64.54K
- Avg volume
- 131.40K
- Open
- 1.85
- Previous close
- 1.84
- Day's range
- 1.78 – 1.96
- 52-week range
- 1.67 – 5.18
- Beta
- 1.51
- Analysts
- Strong Buy
- Price target
- 10.44 (+477.1%)
- Earnings date
- Feb 10, 2025
2Y -1.23 (-40.46%)
Key statistics
- Enterprise value
- 14.15M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.56
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -5.58M
- Total cash
- 19.41M
- Total debt
- 0
- Return on equity
- -18.56%
- Short % of float
- 1.60%
- 50-day average
- 3.44
- 200-day average
- 3.04
Analyst view
Consensus: strong buy
- Target (low)
- 7.79
- Target (mean)
- 10.44
- Target (high)
- 12.30
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 10, 2025
Expected Feb 10, 2025. Consensus EPS estimate -0.45333.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 10, 2025 | Dec 1, 2024 | -0.27 | — | — | — |
| Nov 13, 2024 | Sep 1, 2024 | -0.33 | -0.33 | 0.00 | 0.00% |
About Grace Therapeutics, Inc.
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- acastipharma.com
News
Grace Therapeutics Q1 EPS $(0.91) Misses $(0.18) Estimate 
Grace Therapeutics Receives FDA Meeting Minutes From Type A Meeting; FDA Confirms No Clinical Safety Or Efficacy Deficiencies 
12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
Grace Therapeutics Q4 EPS $(0.06) Beats $(0.15) Estimate 
TD Cowen Maintains Buy on Grace Therapeutics, Lowers Price Target to $8 
Grace Therapeutics Stock Falls As FDA Declines To Approve Brain Hemorrhage Drug - Grace Therapeutics, Inc. Receives FDA Complete Response Letter For GTx-104, No New Clinical Data Required; Intends To Resubmit Application Following Resolution Of Cited Items
- Grace Therapeutics Announces Acceptance Of Abstract Highlighting Results From STRIVE-ON Phase 3 Safety Trial For Presentation At 2026 American Academy of Neurology Meeting, April 18-22
12 Health Care Stocks Moving In Tuesday's Intraday Session - Grace Therapeutics Q3 EPS $(0.14) Beats $(0.28) Estimate
Your note
Sign in to keep a note on GRCE — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Adar1 Capital Management, LLC | 9.46% | 959,571 | 3.51M | Sep 29, 2024 |
| AIGH Capital Management LLC | 6.32% | 641,083 | 2.35M | Sep 29, 2024 |
| Bank of America Corporation | 4.88% | 494,698 | 1.81M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.16% | 16,147 | 59.10K | Sep 29, 2024 |
| National Bank of Canada/FI | 0.03% | 2,719 | 9.95K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.03% | 2,732 | 10.00K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.03% | 3,058 | 11.19K | Oct 30, 2024 |